OC 8491 PREVPVACC: A PHASE III, MAMS ADAPTIVE PROPHYLACTIC HIV VACCINE TRIAL WITH A SECOND RANDOMISATION TO COMPARE F/TAF WITH TDF/FTC PROPHYLAXIS

1Sarah Joseph*, 2Pontiano Kaleebu, 3Eugene Ruzagira, 2Christian Holm Hansen, 1Janet Seeley, 1Vincent Basajja, 1Jonathan Wiwer, 1Iuke Fox, 1Chery Kingsley, 1Saibd Aboud, 1Eligius Iyamuya, 2Lucas Maganga, 1Doreen Pamba, 6Gita Ramjee, 5Justin Yssel, 7Edna Vigeas, 1Ishch Jani, 3Fax Priddy, 8Charlotte Nilsson, 10Jane Krolid, 11Giuseppe Pantaleo, 12Merlin Robb, 13Angela Cook, 14David Dunne, 15Sheena McCormack.

1Imperial College London, UK; 2MRCUVARI and LSHTM Uganda Research Unit; 3King’s College London; 4Muhimbili University of Health and Allied Sciences, Tanzania; 5NIMR-Mbeya Medical Research Center; 6South African Medical Research Council, Cape Town, South Africa; 7Instituto Nacional de Saúde, Maputo, Mozambique; 8International AIDS Vaccine Initiative, New York, USA; 9Public Health Agency of Sweden; 10Hospitalier Universitaire Vaudois, Switzerland; 11Tanzania; 12Kamuzu Central Hospital, Malawi; 13Sheena Mccormack.

OC 8490 INTERACTIVE WORKSHOPS ON USING RAPID DIAGNOSTIC TESTS FOR MENTAL HEALTH AND INFECTION INTEGRATION WITH ART IN URBAN AND RURAL SETTING (GREAT)

1Tomáš Hanke*, 2Patricia Fast, 2Pontiano Kaleebu, 4Walter Jaoko, 5Eduard Sanders, 6William Kilembe, 2Hester Kuipers, 3Pontiano Kaleebu, 4Walter Jaoko, 5Eduard Sanders, 1University of Oxford, UK; 2International AIDS Vaccine Initiative (IAVI), New York, USA; 3IAVI Human Immunology Laboratory (HIL), London, UK

Background DREAMM is an implementation study aiming to reduce meningo-encephalitis related mortality. Delays in diagnosis and treatment through poor access to diagnostics and treatments are significant contributing factors to the ongoing high mortality of HIV-associated central nervous system (CNS) infections, causing up to 25% of all HIV-related deaths in sub-Saharan Africa.

Methods A before-after design is being implemented across 3 sites in Africa; Lilongwe, Malawi, Dar Es Salaam, Tanzania and Yaoundé, Cameroon. The study is composed of 3 phases: Observation, Training and Implementation.

Results The observation phase (audit of practice) happened between November 2016 – May 2017 in Malawi and Tanzania. Overall, 110 patients were included. Ten-week all-cause mortality was 64% (42/66) in Tanzania and 37% (13/35) in Malawi. Approximately 75% of patients were ART experienced. Across sites, 76.6% of patients presented with abnormal mental status, with a median baseline CD4 count of 50 cells/μL. Only 27/55 patients in Tanzania had a lumbar puncture ordered compared to 27/35 in Malawi. All patients in Tanzania received empirical Fluconazole monotherapy whereas almost 1/3 patients in Malawi (11/35) were treated with Amphotericin B which is not readily available in both countries.

The training phase (completed in November 2017 for Malawi and Tanzania) used the train-the-trainer approach. Interactive workshops on using rapid diagnostic tests (RDTs), performing basic microbiological techniques and safe administration of medicines were chosen as the most pertinent to reducing mortality. Patient and laboratory pathways were optimised afterwards by increasing the routine laboratory capacity, performing CSF analysis, providing infectious diseases mentorship for clinicians and procuring RDTs and reagents not locally available.

Implementation is underway in Malawi and Tanzania and the audit phase is scheduled for autumn in Cameroon. Upon completion, the project is expected to create a sustainable approach to reduce the high mortality of HIV-related meningo-encephalitis with the optimised patient and laboratory pathways embedded within routine care.